Kappa light chain myeloma with initial cutaneous involvement.
Saka
Bulent
B
Erten
Nilgun
N
Oztürk
Gulistan
G
Yilmaz
Cengiz
C
Dogan
Oner
O
Buyukbabani
Nesimi
N
Besisik
Sevgi K
SK
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D019008:Drug Resistance, Neoplasm; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007145:Immunoglobulin kappa-Chains / Q000097:blood / Q000276:immunology* / Q000652:urine; D007952:Leukemia, Plasma Cell / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D009378:Neoplasms, Multiple Primary; D016609:Neoplasms, Second Primary; D012871:Skin Diseases / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects
D007145:Immunoglobulin kappa-Chains; D013792:Thalidomide; D003907:Dexamethasone